Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers

Phase 1

Completed

Conditions: Autism Spectrum Disorder

Interventions: Drug: Balovaptan
Drug: Esomeprazole

First Posted Date: 2019-11-07

Last Posted Date: 2021-03-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 16

Registration Number: NCT04156646

Locations: 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Phase 3

Completed

Conditions: Triple-Negative Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Nab-Paclitaxel

First Posted Date: 2019-11-04

Last Posted Date: 2025-01-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 184

Registration Number: NCT04148911

Locations: 🇦🇷
CEMIC, Buenos Aires, Argentina
🇨🇱
Pontificia Universidad Catolica de Chile, Santiago, Chile
🇨🇿
Nemocnice AGEL Novy Jicin a.s., Novy Jicin, Czechia

and more 64 locations

Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Melanoma
Non-small Cell Lung Cancer
Solid Tumors
Esophageal Squamous Cell Carcinoma

Interventions: Drug: RO7247669

First Posted Date: 2019-10-28

Last Posted Date: 2025-03-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 170

Registration Number: NCT04140500

Locations: 🇩🇰
Rigshospitalet, København Ø, Denmark
🇩🇰
Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark
🇬🇪
LLC Arensia Explorer Medicine, Tbilisi, Georgia

and more 22 locations

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME

Phase 3

Recruiting

Conditions: Diabetic Macular Edema

Interventions: Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Intravitreal Ranibizumab 0.5 mg Injection
Drug: Ranibizumab refill exchange

First Posted Date: 2019-09-30

Last Posted Date: 2025-06-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 634

Registration Number: NCT04108156

Locations: 🇺🇸
Sierra Eye Associates, Reno, Nevada, United States
🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸
Retinal Consultants of Arizona;Opthalmology, Phoenix, Arizona, United States

and more 87 locations

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

Phase 3

Active, not recruiting

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2019-09-25

Last Posted Date: 2025-03-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 668

Registration Number: NCT04102098

Locations: 🇸🇬
Tan Tock Seng Hospital, Singapore, Singapore
🇪🇸
Hospital General Universitario Gregorio Marañon, Madrid, Spain
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States

and more 131 locations

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2019-09-16

Last Posted Date: 2024-10-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 43

Registration Number: NCT04091217

Locations: 🇨🇳
Fujian Provincial Cancer Hospital, Fuzhou City, China
🇨🇳
Beijing Cancer Center; Renal Cancer And Melanoma Department., Beijing City, China
🇨🇳
Zhejiang Cancer Hospital, Zhejiang, China

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Phase 2

Completed

Conditions: Moderate to Severe Ulcerative Colitis

Interventions: Drug: Induction- PF-06480605 450 mg SC Q4W
Other: Induction- Placebo SC Q4W
Drug: Induction- PF-06480605 50 mg SC Q4W
Drug: Induction- PF-06480605 150 mg SC Q4W
Drug: Chronic- PF-06480605 50 mg SC Q4W
Drug: Chronic- PF-06480605 150 mg SC Q4W
Drug: Chronic- PF-06480605 450 mg SC Q4W

First Posted Date: 2019-09-16

Last Posted Date: 2024-01-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 246

Registration Number: NCT04090411

Locations: 🇺🇸
Dothan Surgery Center, Dothan, Alabama, United States
🇺🇸
Investigational Drug Services, Philadelphia, Pennsylvania, United States
🇺🇸
Flowers Hospital, Dothan, Alabama, United States

and more 161 locations

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1

Recruiting

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Englumafusp alfa
Drug: Obinutuzumab
Drug: Tocilizumab
Drug: Glofitamab

First Posted Date: 2019-09-04

Last Posted Date: 2025-05-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 498

Registration Number: NCT04077723

Locations: 🇺🇸
City of Hope Medical Center, Pasadena, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States

and more 34 locations

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

Phase 2

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Ocrelizumab

First Posted Date: 2019-08-30

Last Posted Date: 2025-03-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 23

Registration Number: NCT04075266

Locations: 🇮🇹
Ospedale Pediatrico Bambino Gesù, Roma, Lazio, Italy
🇮🇹
Azienda Ospedaliera Sant'Andrea, Roma, Lazio, Italy
🇮🇹
AOU Policlinico V. Emanuele - P.O G. Rodolico, Catania, Sicilia, Italy

and more 9 locations

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Ipatasertib
Drug: Palbociclib
Drug: Fulvestrant

First Posted Date: 2019-08-19

Last Posted Date: 2024-11-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 20

Registration Number: NCT04060862

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇨🇦
Hopital du Saint Sacrement, Quebec City, Quebec, Canada
🇺🇸
Dana-Farber Cancer Institute; GYN Oncology, Boston, Massachusetts, United States

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy